Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s …
Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is now …
Dive Brief: Biogen has withdrawn a request to start selling its Alzheimer’s disease drug in Europe, marking the latest setback in the company’s efforts to …
Medicare will not pay for Biogen’s new Alzheimer’s medicine unless prospective patients are enrolled in a clinical trial, the U.S. government said Thursday in a …
Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes …
Dive Brief: An experimental, fast-acting depression drug from Sage Therapeutics and partner Biogen met its main goals in a closely watched Phase 3 study that …
Dive Brief: Al Sandrock, a former top Biogen executive who led development of the company’s Alzheimer’s drug Aduhelm, is joining the board of directors at …
Biogen recorded $1 million in revenue from its new treatment for Alzheimer’s disease in the last quarter of 2021, offering the latest evidence that the …
Medicare will restrict coverage of Biogen’s controversial Alzheimer’s treatment only to patients who take part in a rigorous clinical trial, the federal government announced Tuesday, …
A crucial study evaluating Biogen’s approved drug for Alzheimer’s disease is set to begin in May, the company disclosed Thursday, and if enrollment goes as …
Aduhelm has come under intense scrutiny since the Food and Drug Administration’s controversial June approval of the drug, the first new Alzheimer’s treatment in decades …
With few treatment options and millions of patients in the U.S. alone, Alzheimer’s has long been one of the biggest targets for drug developers. Yet, …
An experimental drug for amyotrophic lateral sclerosis missed the main goal of a late-stage clinical trial, marking another setback in attempts to treat the debilitating …
A small clinical trial of a once-failed Alzheimer’s drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more …
After numerous setbacks in Alzheimer’s disease, Lilly has high hopes for a breakthrough with donanemab. When the FDA controversially approved Biogen’s Aduhelm in June, it …
The U.S. health department’s inspector general will review how the Food and Drug Administration grants accelerated approvals of new drugs, announcing a broad investigation Wednesday …
